Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9399065B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 12, 2014 |
| Grant date | Jul 26, 2016 |
| Priority date | — |
| Expiry date | May 12, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/183
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.